Authors : Sunil Chaudhry, Sunil Chaudhry
DOI : 10.18231/j.jpbs.2022.005
Volume : 10
Issue : 1
Year : 2022
Page No : 22-28
The median survival of patients with newly diagnosed MM was approximately 2.5 years, before the introduction of Proteasome inhibitors and immunomodulators. Bortezomib, thalidomide, lenalidomide, and the introduction of autologous stem cell transplantation (ASCT) have substantially improved overall survival (OS), which now ranges from 5 to 7 years.Several three-drug (triplet) combination regimens have shown better efficacy in, multiple myeloma. Currently, many MM cell antigens, such as daratumumab which is targeted therapy, vaccines (dendritic cell, myeloma derived protein and peptides) are combined with autologous stem cell transplantation. Treatment of Multiple myeloma expensive ranging between 11000 to 13000 USD.
Keywords: Myeloma, Bortezomib, Proteasome inhibitor, Panobinostat, Daratumumab, Elotuzumab